BioMarin Pharmaceutical Inc. Files 8-K
Ticker: BMRN · Form: 8-K · Filed: Oct 29, 2024 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations, sec-filing
Related Tickers: BMRN
TL;DR
BioMarin filed an 8-K on Oct 29th for financial updates. Details TBD.
AI Summary
BioMarin Pharmaceutical Inc. filed an 8-K on October 29, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signifies a formal update from BioMarin Pharmaceutical Inc. to the SEC regarding its financial status and operational results, which is crucial for investors to monitor company performance.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting operational and financial results, not indicating any immediate adverse events.
Key Players & Entities
- BIOMARIN PHARMACEUTICAL INC (company) — Registrant
- October 29, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 68-0397820 (identifier) — I.R.S. Employer Identification No.
- 770 Lindaro Street San Rafael California 94901 (address) — Address of Principal Executive Offices
- 415-506-6700 (phone_number) — Registrant's telephone number
FAQ
What specific financial results or operational updates are being reported by BioMarin Pharmaceutical Inc. in this 8-K?
The provided text indicates the filing is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not contain the specific details of these results or updates.
When was this 8-K filing submitted to the SEC?
The filing was submitted on October 29, 2024.
What is BioMarin Pharmaceutical Inc.'s state of incorporation?
BioMarin Pharmaceutical Inc. is incorporated in Delaware.
What is the principal executive office address for BioMarin Pharmaceutical Inc.?
The principal executive offices are located at 770 Lindaro Street, San Rafael, California 94901.
What is the purpose of an 8-K filing?
An 8-K filing is used by publicly traded companies to announce major corporate events that shareholders should know about, such as results of operations and financial condition.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-10-29 16:04:25
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market In
Filing Documents
- bmrn-20241029.htm (8-K) — 24KB
- earningsrelease-29oct24ex9.htm (EX-99.1) — 303KB
- bmrnlogoa01a.jpg (GRAPHIC) — 4KB
- 0001048477-24-000149.txt ( ) — 484KB
- bmrn-20241029.xsd (EX-101.SCH) — 2KB
- bmrn-20241029_lab.xml (EX-101.LAB) — 21KB
- bmrn-20241029_pre.xml (EX-101.PRE) — 12KB
- bmrn-20241029_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 29, 2024, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its third quarter ended September 30, 2024. The Company's press release issued on October 29, 2024 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of the Company dated October 29, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: October 29, 2024 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer